Renflexis Alternatives Compared
Renflexis | Entyvio | Humira |
|
---|
Renflexis (infliximab) | Entyvio (vedolizumab) | Humira (adalimumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease, Crohn's Disease - Active, Inflammatory Bowel Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions Ulcerative Colitis
Crohn's Disease
Popular comparisons
|
|||||||||||||||||||||||
More about Renflexis (infliximab) | More about Entyvio (vedolizumab) | More about Humira (adalimumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Renflexis has an average rating of 7.1 out of 10 from a total of 8 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 25% reported a negative effect. |
Entyvio has an average rating of 6.1 out of 10 from a total of 153 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 29% reported a negative effect. |
Humira has an average rating of 6.3 out of 10 from a total of 681 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 32% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Renflexis side effects in more detail. |
See also: Entyvio side effects in more detail. |
See also: Humira side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Renflexis prices |
View all Entyvio prices |
View all Humira prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other infliximab brands include: Avsola, Inflectra, Ixifi, Remicade, Zymfentra | Other vedolizumab brands include: Entyvio Pen | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
228 hours |
600 hours |
480 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 501 drugs are known to interact with Renflexis:
|
A total of 154 drugs are known to interact with Entyvio:
|
A total of 483 drugs are known to interact with Humira:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
May 20, 2014 |
December 31, 2002 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.